Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients
Background Adjuvant immunotherapy and targeted therapy are now the standard of care for patients with resected stage IIIA–IV melanoma. However, little is known regarding its efficacy in real-world patients who were not represented in these landmark trials.Methods This retrospective study included al...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-05-01
|
| Series: | Melanoma Management |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450885.2025.2461963 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|